Floatz Rating
B58/100
Confidence
Indicative
Sponsor
BeOne Medicines
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07226349CT.gov A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06979596CT.gov A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | — | Recruiting | — | — | — |
NCT06997029CT.gov A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07038369CT.gov A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | — | Active Not Recruiting | — | — | — |
NCT06993844CT.gov Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06736704CT.gov SNV4818 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06253195CT.gov BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | — | Completed | — | — | — |
NCT06257264CT.gov A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | — | Active Not Recruiting | — | — | — |
NCT06239467CT.gov First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06208410CT.gov A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | — | Recruiting | — | — | — |
Show 18 more trialsShow fewer
NCT06120283CT.gov BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05867251CT.gov Study of AVZO-021 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06090318CT.gov Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | — | Withdrawn | — | — | — |
NCT06202261CT.gov A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05735080CT.gov Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | — | Recruiting | — | — | — |
NCT05251714CT.gov CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05252416CT.gov (VELA) Study of BLU-222 in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04726332CT.gov Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | — | Terminated | — | — | — |
NCT04282031CT.gov A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT04247126CT.gov A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | — | Completed | — | — | — |
NCT03310541CT.gov AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | — | Completed | — | — | — |
NCT03134638CT.gov A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04524728CT.gov Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy | — | Completed | — | — | — |
NCT02761694CT.gov Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | — | Terminated | — | — | — |
NCT02640755CT.gov Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase | — | Completed | — | — | — |
NCT02404051CT.gov Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01877382CT.gov A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT01655225CT.gov A Study of LY3023414 in Participants With Advanced Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fulvestrant (this asset) | BeOne Medicines | P3 | B · 58 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Fulvestrant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BB · 70 |
| Breast Cancer | — | P4 | BB · 69 |
| Invasive Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fulvestrant in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fulvestrant-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →